Fintel reports that on April 17, 2023, EF Hutton reiterated coverage of Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy recommendation.
Analyst Price Forecast Suggests 318.12% Upside
As of April 6, 2023, the average one-year price target for Adaptimmune Therapeutics is $5.69. The forecasts range from a low of $2.02 to a high of $10.50. The average price target represents an increase of 318.12% from its latest reported closing price of $1.36.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Adaptimmune Therapeutics is $21MM, a decrease of 20.94%. The projected annual non-GAAP EPS is -$0.78.
What are Other Shareholders Doing?
IDNA - iShares Genomics Immunology and Healthcare ETF holds 442K shares representing 0.27% ownership of the company. In it's prior filing, the firm reported owning 432K shares, representing an increase of 2.33%. The firm decreased its portfolio allocation in ADAP by 10.77% over the last quarter.
Jpmorgan Chase holds 1,001K shares representing 0.60% ownership of the company. In it's prior filing, the firm reported owning 1,007K shares, representing a decrease of 0.57%. The firm increased its portfolio allocation in ADAP by 23.93% over the last quarter.
Vigilare Wealth Management holds 29K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 37K shares, representing a decrease of 27.78%. The firm decreased its portfolio allocation in ADAP by 99.95% over the last quarter.
Rathbone Brothers holds 433K shares representing 0.26% ownership of the company. No change in the last quarter.
Key Client Fiduciary Advisors holds 297K shares representing 0.18% ownership of the company. In it's prior filing, the firm reported owning 436K shares, representing a decrease of 46.92%. The firm decreased its portfolio allocation in ADAP by 99.93% over the last quarter.
What is the Fund Sentiment?
There are 87 funds or institutions reporting positions in Adaptimmune Therapeutics.
This is an increase
of
2
owner(s) or 2.35% in the last quarter.
Average portfolio weight of all funds dedicated to ADAP is 0.11%,
an increase
of 32.34%.
Total shares owned by institutions increased
in the last three months by 0.65% to 116,590K shares.
The put/call ratio of ADAP is 0.09, indicating a
bullish
outlook.
Adaptimmune Therapeutics Background Information
(This description is provided by the company.)
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
See all Adaptimmune Therapeutics regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
